Vaccine Platforms
Vaccine Platforms & Antimicrobials
Two defences against germs. Vaccine platforms are ready-made methods, such as mRNA, that turn a new virus's genetic code into a vaccine quickly; one went from an unknown virus to full approval in under two years. Antimicrobials are the medicines that kill bacteria, and here progress is thin: in about eight years only two genuinely new classes of antibiotic were approved anywhere. Same science base, opposite economics, because new antibiotics are kept in reserve and earn little.
Maturity
Where it feeds in
Where you have already met this
Since July 2017, seventeen new antibacterial medicines have been authorised somewhere in the world. Two of them are a new chemical class. In the same stretch, one mRNA vaccine went from a virus nobody had met to full FDA approval on 23 August 2021. Same science base. Opposite economics.
If this moved
If the payment model for antibiotics changed - a fee for having the medicine rather than for selling doses - the antimicrobial half would stop being a market failure. Zoonotic and antimicrobial-resistance risk would still sit where epistemic trust and synthetic biology hold it, so that reading would not move on this alone.
What to watch for
Whether subscription-style payment spreads beyond the NHS scheme, which pays a fixed annual fee instead of a price per dose. The count of agents active against a WHO 'critical' pathogen, which stood at five.
Not to be confused with
Antimicrobial resistance itself, which is the risk this is measured against. Resistance rises with use; the pipeline responds to money, and the two move on different clocks.
What it is
Rapid-response vaccine technologies and the development of new classes of antibiotic and antimicrobial agent.
How it works
- 01The target is identifiedFor a vaccine, a pathogen is sequenced and a surface protein chosen. For an antibiotic, a compound has to be found that kills bacteria without killing the patient - a much smaller search space than it sounds.
- 02A platform swaps the payloadThe point of a platform is that the machinery stays and only the instructions change: a different sequence into the same lipid-nanoparticle format.
- 03Trials establish that it works and is safeSame regulatory road for both halves. Vaccines are trialled in the healthy at scale; reserve antibiotics are trialled in patients who are already very ill, which is slower and smaller.
- 04Manufacture and distributeVaccines go out through national immunisation programmes with public purchasers behind them, which is why uptake is fast when they exist.
- 05Stewardship suppresses the use of a new antibioticA genuinely new antibiotic is reserved for infections nothing else treats. The better it is, the less it is used.
- 06Revenue follows volume - so the antibiotic does not earnPayment per dose rewards the vaccine and punishes the reserve antibiotic. Fixing that is a procurement decision, not a scientific one.
State of play
- Ninety antibacterial agents were in clinical development at 15 February 2025 - 50 traditional antibiotics and 40 non-traditional approaches - and only 15 qualified as innovative (WHO, Analysis of antibacterial agents in clinical and preclinical development, 2 Oct 2025).
- Only 5 of those agents are effective against at least one bacterium on WHO's 'critical' list (WHO, 2 Oct 2025).
- Seventeen new antibacterial medicines have received marketing authorisation since 1 July 2017, of which two represent a new chemical class (WHO, 2 Oct 2025).
- Total vaccine volumes reached 7.2 billion doses in 2024, 7% above 2023, and for COVID-19 mRNA vaccines 95% of that volume came from two manufacturers (WHO, Global Vaccine Market Report 2025, Dec 2025).
- In 2025, 85% of infants worldwide completed three doses of the DTP vaccine, while 13.5 million children received no vaccine at all (WHO and UNICEF, 15 Jul 2026).
- NHS England and NICE pay companies a fixed annual fee for an antimicrobial, based on its benefit to the health service rather than on the volumes used (NHS England, 12 Aug 2024).
Why it matters
It is the enabler standing between a pathogen and a pandemic, and between antimicrobial resistance and a return to pre-antibiotic medicine. Its two halves are moving in opposite directions.
- It is the defence against the megatrend it feeds most directly - zoonotic and antimicrobial-resistance risk, which sits at 2, held there by epistemic trust and synthetic biology.
- The two halves make the book's argument inside a single entry: the same science, opposite incentives, and the incentive decides which half works.
- Where the binding constraint is a payment model, the fix is written by a purchaser. No laboratory result resolves it.
What holds it back
Revenue tied to volume
A reserve antibiotic is valuable precisely because it is rarely used. Paid per dose, it cannot repay its development.
Discovery is genuinely hard
Two new chemical classes in eight years of approvals is not only an economics problem; the chemistry against Gram-negative bacteria is difficult.
Manufacturing concentration
Ninety-five per cent of 2024's COVID-19 mRNA volume came from two manufacturers. Platform capability is mature; access to it is narrow.
Coverage, not capability
Thirteen and a half million children got no vaccine in 2025. The limit there is delivery and confidence, not technology.
Terms
- Platform vaccine
- A manufacturing format - mRNA in a lipid nanoparticle, or a viral vector - where only the genetic payload changes between diseases.
- Pull incentive
- A payment promised for having a medicine available, independent of how many doses are sold.
- Antimicrobial stewardship
- Rules restricting the use of an antibiotic to preserve its effectiveness, which also suppress its sales.
- Priority pathogen list
- WHO's ranking of drug-resistant bacteria by how badly new treatments are needed; 'critical' is its top tier.
- Zero-dose child
- A child who has received no routine vaccine at all - the measure of where delivery, not supply, has failed.
Steepens
| Megatrend | Weight | Role |
|---|---|---|
| Zoonotic and Antimicrobial Resistance Risk | large | |
| Longevity and the Healthspan Gap | moderate | |
| Food System Transformation | moderate |
The gradient behaves like a sticky rubber band: it is pulled hardest toward the weakest enabler. Marginal links are shown but do not pull.
If this moved one step
Computed from the map as it stands: this score raised from 3 to 4, every other score unchanged. It is arithmetic, not a forecast.
Raised one step on its own, it lifts no megatrend's weakest link; each gradient it feeds still rises a little.
The gradient also rises in
- Food System Transformation2.3/5 , 2.3/5
- Longevity and the Healthspan Gap1.8/5 , 1.8/5
- Zoonotic and Antimicrobial Resistance Risk2.5/5 , 2.6/5
What would change the gradient
Conditional, not predictive. No dates, no probabilities.
- 01Pull incentives - subscription or market-entry rewards that decouple revenue from volume
- 02Stewardship, which reduces resistance pressure and cuts revenue further
- 03Surveillance capacity, which determines how early anything is seen
Common misconception
That vaccine platform success implies antimicrobial success. Vaccines had a demonstrated pandemic response; the antibiotic pipeline is nearly empty, and for market reasons rather than scientific ones.
Talin, B. (2026). Vaccine Platforms & Antimicrobials. The Future Explorer, dataset v0.4.0 (2026-11-16). https://explorer.talin.digital/e/vaccine-platforms-and-antimicrobials/